Dr. Brian Johnson
Dr. Brian Johnson received his MD from New York Medical College and has been practicing for more than 20 years.
Dr. Johnson’s research goal is to understand how opioids exert their effects by addressing clinical challenges that appear unrelated but are unified by an innovative theory. Dr. Johnson and his team have proposed a theory that unifies the nature of these disorders by assuming that each involves a dysregulation of the opioid system based on data suggesting that opioid dependence and fibromyalgia are associated with low opioid tone whereas autism is associated with high opioid tone. Their first challenge, therefore, is to create and validate a treatment for opioid dependence that corrects persistent hormonal changes after detoxification. Their second challenge is to treat fibromyalgia. Their third challenge is to assess whether autism is a disease of too-high opioid tone by blocking excess opioid stimulation to treat the symptoms. Opioid dependence, fibromyalgia, and autism are three disorders that cause much distress and disability but are difficult to treat. They test the theory by treating opioid dependence and fibromyalgia with low-dose naltrexone and autism with high-dose naltrexone. Their theory suggests a novel approach that could improve the quality of life of patients suffering from these debilitating disorders.
To view his bio, click on Dr. Brian Johnson’s Profile
To view his published articles, click on Dr. Brian Johnson’s Work
MedInsight® Research Institute.
All rights reserved.
About LDNscience®
LDNscience® is a public information project of the MedInsight® Research Institute.
MedInsight® Research Institute is a U.S./U.K. based non-profit organization which serves as a platform for researching and indexing available off-label (repurposed) treatments for cancer and chronic diseases.
MedInsight's Projects:
Dipyridamole Eye Drops
Cureiosity®
